Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 4, 2015, Pages 582-586

  Ohya, Hiroki ^a   Shibayama, Yoshihiko ^a   Ogura, Jiro ^a   Narumi, Katsuya ^a   Kobayashi, Masaki ^a   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

IC50; Multidrug resistance protein 2; Organic anion transporting polypeptide 1B1; Regorafenib; Vectorial drug transport

Indexed keywords

ESTRONE SULFATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; REGORAFENIB; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; VERLUKAST; CARBANILAMIDE DERIVATIVE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; PROPIONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; HEK293 CELL LINE; LLC PK1 CELL LINE; METABOLISM; PIG; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; LLC-PK1 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; PHENYLUREA COMPOUNDS; PROPIONATES; PYRIDINES; QUINOLINES; SWINE;

EID: 84929492330     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00740     Document Type: Article

References (21)

1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/phar-macodynamic relationship. Clin. Cancer Res., 9, 327-337 (2003).
2. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 64, 7099-7109 (2004).
3. Dietrich CG, Geier A, Oude Elferink R P. ABC of oral bioavail-ability: transporters as gatekeepers in the gut. Gut, 52, 1788-1795 (2003).
4. König J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta, 1461, 377-394 (1999).
5. Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther., 302, 407-415 (2002).
6. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu. Rev. Pharmacol. Toxicol., 52, 135-151 (2012).
7. Khurana V, Minocha M, Pal D, Mitra AK. Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabol. Drug Interact., 29, 179-190 (2014).
8. Khurana V, Minocha M, Pal D, Mitra AK. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabol. Drug Interact., 29, 249-259 (2014).
9. Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br. J. Cancer, 110, 894-898 (2014).
10. Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Drug interactions with solid tumor-targeted therapies. Crit. Rev. Oncol. Hematol., 89, 179-196 (2014).
11. Mukai M, Che XF, Furukawa T, Sumizawa T, Aoki S, Ren XQ, Ha-raguchi M, Sugimoto Y, Kobayashi M, Takamatsu H, Akiyama S. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci., 94, 557-563 (2003).
12. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama S. Effect of multidrug resistance-reversing agents on transporting activity of human cana-licular multispecific organic anion transporter. Mol. Pharmacol., 56, 1219-1228 (1999).
13. Yamaguchi H, Takeuchi T, Okada M, Kobayashi M, Unno M, Abe T, Goto J, Hishinuma T, Shimada M, Mano N. Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol. Pharm. Bull., 34, 389-395 (2011).
14. Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, Sugawara M, Iseki K, Takeda Y, Yamada K. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol. Pharm. Bull., 34, 433-435 (2011).
15. van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ, Hartigh J. Hartigh Jd. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci., 937, 33-43 (2013).
16. He M, Wei MJ. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin. J. Cancer, 31, 126-133 (2012).
17. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res., 14, 3141-3148 (2008).
18. Pharmaceutical and Medical Devices Agency, Japan. "The review report of stivarga tablets 40 mg.": http://www.pmda.go.jp/english/service/pdf/drugs/stivarga-mar2010-e.pdf, cited 15 March, 2013.
19. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res., 22, 1559-1577 (2005).
20. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther., 318, 395-402 (2006).
21. Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H, Mitsunaga S, Hashizume K, Ito Y, Sasaki Y. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest. New Drugs, 32, 104-112 (2014).